JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Inclusion Criteria:

• Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Must be able to provide an archived tumor sample

• Must have histologically or cytologically confirmed metastatic or locally advancedsolid tumor

• Dose Expansion phase cohorts must meet specific expression or gene mutationwhere indicated

• Must be refractory to or become intolerant of existing therapy(ies) known to provideclinical benefit for their condition

• Must have at least 1 measurable lesion per RECIST v1.1

• Must have adequate organ functions

• Must be able to swallow and retain orally administered medication

Exclusion Criteria:

• Has central nervous system (CNS) metastases or carcinomatous meningitis, except ifCNS metastases treated and no evidence of radiographic progression or hemorrhage forat least 28 days

• Active infection requiring systemic treatment within 7 days

• Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV

• Any severe and/or uncontrolled medical conditions

• left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) ormultigated acquisition scan (MUGA)

• QT interval using Fridericia's formula (QTcF) interval >470 msec

• Experiencing unresolved CTCAE 5.0 Grade >1 toxicities

• Clinically significant eye disorders